Company: DVAX
Filing Date: 2025-04-15
Form Type: PRER14A
Source: 0000930413-25-001254
Chunk: 41

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-04-15
Form: PRER14A
Chunk 41
---
 and Corporate Governance Committee considers director candidates recommended or nominated by stockholders.
As part of the annual board assessment process, the Nominating and Corporate Governance Committee considers the skills and experience
that best serve Dynavax and the Board and addresses gaps or succession issues.

When selecting candidates for recommendation to the Board, the Nominating and Corporate Governance Committee
considers the attributes of the candidates and the needs of the Board and strives to review all candidates in the same manner,
regardless of the source of the recommendation. In evaluating director nominees, a candidate is expected to have certain minimum
qualifications, including industry experience, financial literacy, integrity and adherence to highest ethical standards, leadership
ability, mature judgment and being able to work collegially with others. In addition, factors such as the following may be considered:

| • | the independence standards as set forth in the applicable Nasdaq listing standards;                                                 |
| • | the presence of any material interests that could cause a conflict between our interests and the interests of the director          
 nominee;                                                                                                                            |
| • | the director nominee’s ability to make independent analytical inquiries and exercise his or her best business judgment              
 in the interest of all stockholders;                                                                                                |
| • | the director nominee’s demonstrated knowledge, skills and experience at high levels in successful organizations;                    |
| • | the director nominee’s experience relevant to our operations, including vaccine commercial operations, vaccine and                  
 other clinical development, business development, finance and capital allocation, risk management, and public health and government 
 affairs in light of prevailing business conditions and the knowledge, skills and experience already possessed by other members      
 of the Board;                                                                                                                       |
| • | leadership ability and a proven record of accomplishment;                                                                           |
| • | the director nominee’s ability to devote sufficient time to the business of the Board and at least one of the standing              
 committees of the Board, in light of the number of other boards on which the director nominee serves and the other business         
 and professional commitments of the director nominee;                                                                               |
| • | the appropriate size and the diversity of the Board;                                                                                |
| • | how the director nominee’s skills and experience would complement and enhance the Board’s overall mix of skills                     
 and experience; and                                                                                                                 |
| • | the director nominee’s experience with accounting rules and practices.                                                              |

Before the Nominating and Corporate Governance Committee recommends a qualified director nominee to the Board
for consideration, the nominee is interviewed by each Nominating and Corporate Governance Committee member as well as the Chairperson
of